Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Safety and Efficacy of Combination Saxagliptin & Dapagliflozin Added to Metformin to Treat Subjects With Type 2 Diabetes

This study has been completed.
Information provided by (Responsible Party):
AstraZeneca Identifier:
First received: May 23, 2012
Last updated: May 30, 2016
Last verified: May 2016
The purpose of this study is to learn if a combination of BMS-477118 (Saxagliptin) and BMS -512148 (Dapagliflozin) added to Metformin can improve (decrease) Glycosylated Hemoglobin (Hemoglobin A1c) in patients with type 2 diabetes after 24 weeks of treatment. The safety of this treatment will also be studied.

Condition Intervention Phase
Type 2 Diabetes
Drug: Saxagliptin
Drug: Metformin XR
Drug: Dapagliflozin
Drug: Placebo matching with Dapagliflozin
Drug: Placebo matching with Saxagliptin
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator)
Primary Purpose: Treatment
Official Title: A Multicenter, Randomized, Double-Blind, Active Controlled, Parallel Group, Phase 3 Trial to Evaluate the Safety and Efficacy of Add-On Therapy With Saxagliptin and Dapagliflozin Added to Metformin Compared to Add-On Therapy With Saxagliptin in Combination With Metformin or Dapagliflozin in Combination With Metformin in Subjects With Type 2 Diabetes Who Have Inadequate Glycemic Control on Metformin Alone.

Resource links provided by NLM:

Further study details as provided by AstraZeneca:

Primary Outcome Measures:
  • Adjusted Mean Change From Baseline in HbA1c at Week 24 [ Time Frame: Baseline (Week 0) and at Week 24 ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Adjusted Mean Change From Baseline in 2-hour Post-prandial Glucose During a Liquid Meal Test (2-h MTT) [ Time Frame: Baseline (Week 0) and at Week 24 ] [ Designated as safety issue: No ]
  • Adjusted Mean Change From Baseline in Fasting Plasma Glucose (FPG) [ Time Frame: Baseline (Week 0) and at Week 24 ] [ Designated as safety issue: No ]
  • Adjusted Percentage of Subjects Achieving Glycemic Response Defined as Glycosylated Hemoglobin (HbA1c) < 7% [ Time Frame: At Week 24 ] [ Designated as safety issue: No ]
  • Adjusted Mean Change From Baseline in Body Weight at Week 24 With the Addition of Saxagliptin and Dapagliflozin to Metformin vs. the Addition of Placebo and Saxagliptin to Metformin [ Time Frame: Baseline (Week 0) and at Week 24 ] [ Designated as safety issue: No ]

Enrollment: 1282
Study Start Date: July 2012
Study Completion Date: January 2014
Primary Completion Date: January 2014 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: Arm 1: Saxagliptin+Metformin XR+Placebo Drug: Saxagliptin
Tablets, Oral, 5mg , Once daily, 24 weeks
Other Name: Onglyza
Drug: Metformin XR
Tablets, Oral, ≥ 1500mg/≤ 2000mg, Once daily, 24 weeks
Other Name: Glucophage XR
Drug: Placebo matching with Dapagliflozin
Tablets, Oral, 0mg, Once daily, 24 weeks
Active Comparator: Arm 2: Dapagliflozin+Metformin XR+Placebo Drug: Metformin XR
Tablets, Oral, ≥ 1500mg/≤ 2000mg, Once daily, 24 weeks
Other Name: Glucophage XR
Drug: Dapagliflozin
Tablets, Oral, 10mg , Once daily, 24 weeks
Other Name: BMS-512148
Drug: Placebo matching with Saxagliptin
Tablets, Oral, 0mg, Once daily, 24 weeks
Experimental: Arm 3: Saxagliptin+Dapagliflozin+Metformin XR Drug: Saxagliptin
Tablets, Oral, 5mg , Once daily, 24 weeks
Other Name: Onglyza
Drug: Metformin XR
Tablets, Oral, ≥ 1500mg/≤ 2000mg, Once daily, 24 weeks
Other Name: Glucophage XR
Drug: Dapagliflozin
Tablets, Oral, 10mg , Once daily, 24 weeks
Other Name: BMS-512148


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Subjects with Type 2 diabetes mellitus (T2DM) with HbA1c ≥ 8.0% and ≤ 12.0%
  • Stable metformin therapy dose of ≥ 1500mg for at least 8 weeks prior to screening
  • Body mass index (BMI) ≤ 45.0kg/m2

Exclusion Criteria:

  • Estimated glomerular filtration rate (eGFR) < 60mL/min/1,73m2 and Serum Creatinine (Scr) ≥ 1.5 mg/dL in males or ≥ 1.4 mg/dL in females
  • Uncontrolled hypertension Systolic Blood Pressure (SBP) ≥ 160mmHg and/or Diastolic Blood Pressure (DBP) ≥ 100mmHg
  • Hepatic disease
  • Cardiovascular disease within 3 months
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01606007

  Hide Study Locations
United States, Alabama
Central Alabama Research
Birmingham, Alabama, United States, 35209
Central Alabama Research
Homewood, Alabama, United States, 35244
Terence T. Hart, Md
Muscle Shoals, Alabama, United States, 35662
International Institute Of Clinical Research
Ozark, Alabama, United States, 36360
United States, Arizona
Clinical Research Advantage
Mesa, Arizona, United States, 85206
Elite Clinical Studies, Llc
Phoenix, Arizona, United States, 85018
Genova Clinical Research
Tucson, Arizona, United States, 85704
United States, Arkansas
Medical Investigations, Inc.
Little Rock, Arkansas, United States, 72205
Aureus Research, Inc.
Little Rock, Arkansas, United States, 72211
United States, California
Southland Clinical Research Center, Inc.
Fountain Valley, California, United States, 92708
Torrance Clinical Research
Lomita, California, United States, 90717
National Research Inst
Los Angeles, California, United States, 90057
Providence Clinical Research
North Hollywood, California, United States, 91606
Diabetes Medical Center Of California
Northridge, California, United States, 91325
Mehrdad Kevin Ariani Md, Inc.
Northridge, California, United States, 91325
Lucita M. Cruz,Md.,Inc.
Norwalk, California, United States, 90650
Center For Clinical Trials, Llc.
Paramount, California, United States, 90723
Center For Clinical Trials Of Sacramento, Inc.
Sacramento, California, United States, 95823
Trinitas Research, Inc
San Jose, California, United States, 95116
Orange County Research Center
Tustin, California, United States, 92780
United States, Colorado
Clinical Research Advantage
Colorado Springs, Colorado, United States, 80906
Infocus Clinical Research
Denver, Colorado, United States, 80211
Lynn Institute Of Denver
Denver, Colorado, United States, 80246
United States, Florida
Southeast Clinical Research, Llc
Chiefland, Florida, United States, 32626
Clinical Therapeutics Corporation
Coral Gables, Florida, United States, 33134
Southeast Clinical Research, Llc
Jacksonville, Florida, United States, 32216
Fpa Clinical Research
Kissimmee, Florida, United States, 34741
Newphase Clinical Trials, Inc.
Miami Beach, Florida, United States, 33140
Clinical Research Of Miami, Inc.
Miami, Florida, United States, 33126
Advanced Pharma Cr, Llc
Miami, Florida, United States, 33136
Omega Research Consultants, Llc
Orlando, Florida, United States, 32804
Palm Harbor Medical Associates
Palm Harbor, Florida, United States, 34684
Andres Patron, Do Pa
Pembroke Pines, Florida, United States, 33026
United States, Georgia
Endocrine Research Solutions, Inc.
Roswell, Georgia, United States, 30076
United States, Illinois
Cedar Crosse Research Center
Chicago, Illinois, United States, 60607-4559
Deerbrook Medical Associates
Vernon Hills, Illinois, United States, 60061
United States, Iowa
Clinical Research Advantage
Council Bluffs, Iowa, United States, 51503
United States, Louisiana
Horizon Research Group Of Opelousas, Llc
Eunice, Louisiana, United States, 70535
United States, Michigan
Associated Internal Medicine Specialists
Battle Creek, Michigan, United States, 49015
Harris And Associates, P.C.
Detroit, Michigan, United States, 48235
United States, Missouri
Patterson Medical Clinic
Florissant, Missouri, United States, 63031
United States, Nebraska
Bellevue Family Practice
Bellevue, Nebraska, United States, 68005
Clinical Research Advantage
Elkhorn, Nebraska, United States, 68022
Clinical Research Advantage
Fremont, Nebraska, United States, 68025
Clinical Research Advantage
Omaha, Nebraska, United States, 68130
United States, New Jersey
South Jersey Medical Associates, P.A.
Blackwood, New Jersey, United States, 08012
Central Jersey Health And Medical Research
Elizabeth, New Jersey, United States, 07205
United States, New York
Southgate Medical Group
West Seneca, New York, United States, 14224
United States, North Carolina
Metrolina Internal Medicine
Charlotte, North Carolina, United States, 28204
Triad Clinical Trials, Llc
Greensboro, North Carolina, United States, 27410
Diabetes & Endocrinology Consultants
Morehead City, North Carolina, United States, 28557
Pmg Research Of Winston-Salem, Llc
Winston-salem, North Carolina, United States, 27103
United States, Ohio
Daystar Clinical Resarch, Inc.
Akron, Ohio, United States, 44313
Sterling Research Grp, Ltd.
Cincinnati, Ohio, United States, 45246
Rapid Medical Research, Inc.
Cleveland, Ohio, United States, 44122
Primed Clinical Research
Dayton, Ohio, United States, 45419
Physicians Research, Inc.
Zanesville, Ohio, United States, 43701
United States, Oklahoma
Lynn Institute Of Norman
Norman, Oklahoma, United States, 73069
United States, Oregon
Willamette Valley Clinical Studies
Eugene, Oregon, United States, 97404
Oregon Clinical Research
Portland, Oregon, United States, 97220
United States, Pennsylvania
Heritage Valley Medical Group
Beaver, Pennsylvania, United States, 15009
Wellmon Family Practice
Shippensburg, Pennsylvania, United States, 17257
United States, South Carolina
Tlm Medical Services
Columbia, South Carolina, United States, 29204
Palmetto Clinical Trial Services Llc
Fountain Inn, South Carolina, United States, 29644
United States, Tennessee
Holston Medical Group
Bristol, Tennessee, United States, 37620
Holston Medical Group
Kingsport, Tennessee, United States, 37660
Pmg Research Of Knoxville
Knoxville, Tennessee, United States, 37912
United States, Texas
Arlington Family Research Center, Inc.
Arlington, Texas, United States, 76012
Padre Coast Clinical Research
Corpus Christi, Texas, United States, 78404
Dallas Diabetes & Endocrine Center
Dallas, Texas, United States, 75230-2548
Excel Clinical Research, Llc
Houston, Texas, United States, 77035
North Hills Medical Research, Inc.
North Richland Hills, Texas, United States, 76180
Med-Olam Clinical Research
Pasadena, Texas, United States, 77504
Sam Clinical Research Center
San Antoinio, Texas, United States, 78229
Covenant Clinical Research, Pa
San Antonio, Texas, United States, 78229
Hillcrest Family Health Center
Waco, Texas, United States, 76710
United States, Utah
Val R. Hansen, M.D.
Bountiful, Utah, United States, 84010
Highland Clinical Research
Salt Lake City, Utah, United States, 84124
United States, Vermont
Southwestern Vermont Med Cntr
Bennington, Vermont, United States, 05201
United States, Virginia
Hampton Roads Center For Clinical Research, Inc.
Suffolk, Virginia, United States, 23435
Canada, British Columbia
Local Institution
Coquitlam, British Columbia, Canada, V3K 3V9
Canada, Manitoba
Local Institution
Winnipeg, Manitoba, Canada, R3E3P4
Canada, Ontario
Local Institution
Brampton, Ontario, Canada, L6T 0G1
Local Institution
Smiths Falls, Ontario, Canada, K7A 4W8
Local Institution
Toronto, Ontario, Canada, M9W 4L6
Canada, Quebec
Local Institution
Granby, Quebec, Canada, J2G 8Z9
Canada, Saskatchewan
Local Institution
Saskatoon, Saskatchewan, Canada, S7K 3H3
Local Institution
Quebec, Canada, G1N 4V3
Korea, Republic of
Local Institution
Bucheon, Gyeonggi-do, Korea, Republic of, 420-717
Local Institution
Sungnam-si, Gyeonggi-do, Korea, Republic of, 463-712
Local Institution
Daegu, Korea, Republic of, 700-721
Local Institution
Incheon, Korea, Republic of, 405-760
Local Institution
Seoul, Korea, Republic of, 110-774
Local Institution
Seoul, Korea, Republic of, 120-752
Local Institution
Seoul, Korea, Republic of, 137-701
Local Institution
Guadalajara, Jalisco, Mexico, 44670
Local Institution
Cuautla, Morelos, Mexico, 62744
Local Institution
Monterrey, Nuevo Leon, Mexico, 64460
Local Institution
Monterrey, Nuevo Leon, Mexico, 64710
Local Institution
Merida, Yucatan, Mexico, 97070
Local Institution
Aguascalientes, Mexico, 20230
Local Institution
Chihuahua, Mexico, 31217
Local Institution
Durango, Mexico, 34000
Local Institution
Gdansk, Poland, 80-546
Local Institution
Katowice, Poland, 40-057
Local Institution
Katowice, Poland, 40954
Local Institution
Krakow, Poland, 30-015
Local Institution
Lodz, Poland, 90-242
Local Institution
Opole, Poland, 45-367
Local Institution
Poznan, Poland, 61-655
Local Institution
Pulawy, Poland, 24-100
Local Institution
Warszawa, Poland, 03-580
Puerto Rico
Local Institution
Cidra, Puerto Rico, 00739
Local Institution
Manati, Puerto Rico, 00674
Local Institution
Ponce, Puerto Rico, 00716
Local Institution
San Juan, Puerto Rico, 00909
Local Institution
San Juan, Puerto Rico, 00926
Local Institution
San Juan, Puerto Rico, 00935
Local Institution
Villa Fontana, Puerto Rico, 00983
Local Institution
Ploiesti, Prahova, Romania, 100018
Local Institution
Ploiesti, Prahova, Romania, 100163
Local Institution
Timisoara, Timis, Romania, 300736
Local Institution
Bucharest, Romania, 050538
Local Institution
Bucuresti, Romania, 020359
Local Institution
Bucuresti, Romania, 020475
Local Institution
Bucuresti, Romania, 11794
Local Institution
Cluj Napoca Cluj, Romania, 400006
Local Institution
Craiova, Romania, 200349
Local Institution
Galati, Romania, 800098
South Africa
Local Institution
Soweto, Gauteng, South Africa, 2013
Local Institution
Gauteng, Johannesburg, South Africa, 1818
Local Institution
Durban, Kwa-Zulu Natal, South Africa, 4001
Local Institution
Cape Town, Western Cape, South Africa, 7500
Local Institution
Goodwood, Western Cape, South Africa, 7460
Local Institution
Paarl, Western Cape, South Africa, 7646
Local Institution
Rondebosch, Western Cape, South Africa, 7700
Local Institution
Somerset West, Western Cape, South Africa, 7130
Local Institution
Johannesburg, South Africa, 1829
Local Institution
Johannesburg, South Africa, 2129
Sponsors and Collaborators
Study Director: Bristol-Myers Squibb Bristol-Myers Squibb
  More Information

Additional Information:
Responsible Party: AstraZeneca Identifier: NCT01606007     History of Changes
Other Study ID Numbers: CV181-169  2012-000679-18 
Study First Received: May 23, 2012
Results First Received: December 19, 2014
Last Updated: May 30, 2016
Health Authority: United States: Institutional Review Board
United States: Food and Drug Administration
Canada: Health Canada
Mexico: Federal Commission for Protection Against Health Risks
Germany: Federal Institute for Drugs and Medical Devices
Brazil: Ethics Committee
Brazil: National Committee of Ethics in Research
Brazil: National Health Surveillance Agency
Argentina: Administracion Nacional de Medicamentos, Alimentos y Tecnologia Medica
Poland: Ethics Committee
Poland: Office for Registration of Medicinal Products, Medical Devices and Biocidal Products
Romania: Ethics Committee
Romania: National Agency for Medicines and Medical Devices
South Korea: Institutional Review Board
South Korea: Korea Food and Drug Administration (KFDA)
South Africa: Department of Health
South Africa: Human Research Ethics Committee
South Africa: Medicines Control Council
South Africa: National Health Research Ethics Council
Italy: Ethics Committee
Italy: The Italian Medicines Agency
India: Drugs Controller General of India
India: Institutional Review Board

Additional relevant MeSH terms:
Diabetes Mellitus
Diabetes Mellitus, Type 2
Glucose Metabolism Disorders
Metabolic Diseases
Endocrine System Diseases
Hypoglycemic Agents
Physiological Effects of Drugs
Hormones, Hormone Substitutes, and Hormone Antagonists
Dipeptidyl-Peptidase IV Inhibitors
Protease Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action processed this record on September 30, 2016